Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Connect Biopharma Holdings Limited - American Depositary Shares (NQ:CNTB)

2.380 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,421
Open 2.380
Bid (Size) 2.380 (10)
Ask (Size) 2.400 (19)
Prev. Close 2.380
Today's Range 2.380 - 2.380
52wk Range 0.5100 - 2.860
Shares Outstanding 55,041,247
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Connect Biopharma Appoints Industry Veteran Jim Schoeneck to its Board of Directors
From Connect Biopharma Holdings Limited
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga

Performance

YTD
+96.7%
+96.7%
1 Month
+144.1%
+144.1%
3 Month
+240.1%
+240.1%
6 Month
+126.7%
+126.7%
1 Year
+85.9%
+85.9%

More News

Read More
Connect Biopharma Announces Plans to Terminate its American Depositary Receipt Program and Directly List its Ordinary Shares on Nasdaq
From Connect Biopharma Holdings Limited
Via GlobeNewswire
Connect Biopharma to Participate in the BTIG Virtual Biotechnology Conference
From Connect Biopharma Holdings Limited
Via GlobeNewswire
Connect Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
From Connect Biopharma Holdings Limited
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Connect Biopharma’s Exclusive Licensee in China, Simcere Pharmaceutical, Announced Submission of its New Drug Application for Rademikibart for the Treatment of Atopic Dermatitis in China
From Connect Biopharma Holdings Limited
Via GlobeNewswire
Connect Biopharma Presents Data Supporting Rademikibart at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress
From Connect Biopharma Holdings Limited
Via GlobeNewswire
Connect Biopharma Announces Two Oral Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress
From Connect Biopharma Holdings Limited
Via GlobeNewswire
Connect Biopharma to Present at Two Upcoming Investor Conferences in June
From Connect Biopharma Holdings Limited
Via GlobeNewswire
Connect Biopharma Presents Data Supporting Development of Rademikibart at the American Thoracic Society (ATS) 2025 International Conference
From Connect Biopharma Holdings Limited
Via GlobeNewswire
Connect Biopharma Reports First Quarter 2025 Financial Results and Provides Business Update
From Connect Biopharma Holdings Limited
Via GlobeNewswire
Connect Biopharma Initiates Phase 2 Seabreeze STAT COPD Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in COPD
From Connect Biopharma Holdings Limited
Via GlobeNewswire
Connect Biopharma Initiates Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma
From Connect Biopharma Holdings Limited
Via GlobeNewswire
Connect Biopharma Announces Multiple Presentations at the American Thoracic Society (ATS) 2025 International Conference
From Connect Biopharma Holdings Limited
Via GlobeNewswire
Tuesday's after hours session: top gainers and losers
Via Chartmill
Bullfrog AI and Connect Biopharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESS Newswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Connect Biopharma Announces Positive Type C Meeting with the FDA for Rademikibart
From Connect Biopharma Holdings Limited
Via GlobeNewswire
Connect Biopharma Announces Publication of Positive Data from Global Phase 2 Trial of Rademikibart in Patients with Moderate-to-Severe Uncontrolled Asthma
From Connect Biopharma Holdings Limited
Via GlobeNewswire
Connect Biopharma Reports 2024 Full-Year Financial Results and Provides Business Update
From Connect Biopharma Holdings Limited
Via GlobeNewswire
Connect Biopharma Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
From Connect Biopharma Holdings Limited
Via GlobeNewswire
Connect Biopharma to Present at Two Upcoming Investor Conferences
From Connect Biopharma Holdings Limited
Via GlobeNewswire
David Szekeres, President of Connect Biopharma Holdings Limited (NASDAQ: CNTB), to Present at NobleCon20
Via Investor Brand Network
Attovia Therapeutics Appoints Chief Financial Officer
From Attovia Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Connect Biopharma Holdings Limited - American Depositary Shares publicly traded?
Yes, Connect Biopharma Holdings Limited - American Depositary Shares is publicly traded.
What exchange does Connect Biopharma Holdings Limited - American Depositary Shares trade on?
Connect Biopharma Holdings Limited - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Connect Biopharma Holdings Limited - American Depositary Shares?
The ticker symbol for Connect Biopharma Holdings Limited - American Depositary Shares is CNTB on the Nasdaq Stock Market
What is the current price of Connect Biopharma Holdings Limited - American Depositary Shares?
The current price of Connect Biopharma Holdings Limited - American Depositary Shares is 2.380
When was Connect Biopharma Holdings Limited - American Depositary Shares last traded?
The last trade of Connect Biopharma Holdings Limited - American Depositary Shares was at 07/22/25 04:00 PM ET
What is the market capitalization of Connect Biopharma Holdings Limited - American Depositary Shares?
The market capitalization of Connect Biopharma Holdings Limited - American Depositary Shares is 131.00M
How many shares of Connect Biopharma Holdings Limited - American Depositary Shares are outstanding?
Connect Biopharma Holdings Limited - American Depositary Shares has 131M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.